Through every step of the engagement, from strategic positioning to closing, Outcome Capital far exceeded expectations. Outcome’s team are knowledgeable advisors with unique domain expertise across the value chain. I wouldn’t look further than Outcome for any life science transaction.
I don’t know where else you would find an investment bank with such expertise. They could move from financial and strategic discussions to highly scientific, clinical discussions with ease. In the end, they brought all these perspectives to bear, developing an exceptional strategy that created value for our company.
Outcome Capital has demonstrated an astute and insightful understanding of our value proposal and the major companies in the cardiovascular space. They provided us with invaluable strategic advice and I can’t think of better partners to have guided us through the process.
They understood our technology and business as well as anyone.
Outcome worked diligently with our executives and board to develop and communicate a strategy that was instrumental in enhancing the value of our company. Their business acumen and knowledge of our market space drove a complex transaction to a very successful close.
Advanced Uro-Solutions engaged the services of Outcome Capital late in the process of being acquired. Outcome Capital took control of all further negotiations and masterfully increased the value of our final offering. The added value Outcome Capital was responsible for was 10 times greater than the value we invested in their services. Our only regret was in not bringing them on sooner. Arnie and Oded brought an amazing team of talented, organized and highly effective individuals. We could NOT have been more satisfied.
With the assistance of Outcome’s recognized expertise in the biomedical field, GenePOC was able to devise and communicate a market-aligned strategy leading to the completion a transaction efficiently and effectively. We are very pleased with the way Outcome supported us throughout this process.
I knew Outcome by reputation, and they were the only group I felt comfortable engaging with and trusting with this deal. What they provided exceeded my expectations not only in value, but also in their conduct and earnestness. It was a pleasure doing business with Outcome Capital.
I thank the Outcome team for driving the Verrix acquisition to completion, for protecting our interests and for an excellent job in navigating the bumps along the way. The Outcome team ran a solid competitive process that caused the market to speak toward a transaction for the benefit of both buyer and seller.
Outcome Capital was a true partner and collaborator starting from the evaluation and sourcing phase. Their teamwork and attention to detail was perfectly accompanied by their knowledge and expertise with the industry segment. Furthermore, their diligence prep rigor was extremely useful once we got to the post term-sheet/closing phase of the transaction. I could not have survived this transaction without their help.
We cannot thank you enough. We appreciate your guidance, expertise, candor, and the fact that you really care. What a great way to do business.
From advances in personalized medicine and diagnostics to transformations in medical devices and therapeutics — not only are avenues of patient care changing but also the financial landscape and fluid interplay between life sciences sectors. The Outcome Capital Life Sciences team is dedicated to following the most recent scientific advancements as well as understanding their implications on market dynamics. The unmatched combination of scientific backgrounds and business acumen of Outcome professionals ensures they see the value of their clients’ businesses not only in today’s market but also the future potential enabling them to maximize value for their clients. Outcome Capital is a trusted partner to middle-market companies providing M&A, capital raise and advisory services in life sciences markets.
Boston – November 8, 2023 Outcome Capital, a specialized life science advisory and investment banking firm, today announced that Electronic Registry Systems, Inc. (ERS), a leading provider of cancer registry solutions and compliance and informatics services, has been acquired by Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a healthcare technology and data analytics company with […]Read More
Outcome Capital Life Science Market Pulse October 2023 Click to view our LifeSciences Pulse NewsletterDownload